Regenerative Medicine in Action: Topical PP405 Shows Promise in Androgenetic Alopecia
PP405, an investigational topical therapy for androgenetic alopecia, met its primary safety endpoint and secondary pharmacokinetic endpoint in a Phase 2a clinical trial, PP405 maker Pelage reports.